/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend.
The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.
Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time The Phase IIb clinical trial results further demonstrated the potential of ASC22+NAs treatment as a functional cure for CHB On-treatment ALT flares might be used as a predictor or monitor of patients' responses to the CHB treatment HANGZHOU, China and SHAOXING, China, June 27, 2022 /PRNewswire/ Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the latest Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) at an oral parallel session of the International Liver Congress 2022 (ILC 2022) held by the European Association for the Study of the Liver (EASL). The interim report is based on a randomized, single-blind, multi-center Phase IIb clinical trial to assess the efficacy and safety of ASC22 in treatment of CHB